• Explore /
  • Poster
  • / NEO-GAP: A phase II single-arm prospective feasibility study of neoadjuvant gemcitabine/cisplatin/nab-paclitaxel for resectable high-risk intrahepatic cholangiocarcinoma.

NEO-GAP: A phase II single-arm prospective feasibility study of neoadjuvant gemcitabine/cisplatin/nab-paclitaxel for resectable high-risk intrahepatic cholangiocarcinoma.

Abstract Poster

Authors

null

Shishir K. Maithel

Winship Cancer Institute, Emory University, Atlanta, GA

Shishir K. Maithel , Milind M. Javle , Amit Mahipal , Bruce Shih-Li Lin , Mehmet Akce , Jeffrey M. Switchenko , Manali Rupji , Hop Tran Cao , Sean P. Cleary , Flavio G. Rocha

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2022 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Track

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Sub Track

Hepatobiliary Cancer

Clinical Trial Registration Number

NCT03579771

Citation

J Clin Oncol 40, 2022 (suppl 16; abstr 4097)

DOI

10.1200/JCO.2022.40.16_suppl.4097

Abstract #

4097

Poster Bd #

84

Abstract Disclosures

Similar Posters

First Author: Emerson Yu-sheng Chen

First Author: Derek B. Grose

First Author: Hailiang Zhang

First Author: Vincent Chung